Fresenius Medical Care AG & Co. KGaA
FMS · NYSE
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 19.40B | 4.89B | 1.51B | 673.41M | 0.57 |
| 2023 FY | 19.45B | 4.93B | 1.37B | 499.00M | 0.85 |
| 2024 FY | 19.34B | 4.76B | 1.47B | 537.91M | 0.92 |
| 2025 FY | 19.63B | 5.03B | 1.83B | 978.37M | 1.68 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 35.75B | 20.30B | 1.27B | 13.21B | 13.99B |
| 2023 FY | 33.93B | 19.10B | 1.40B | 12.08B | 13.62B |
| 2024 FY | 33.57B | 17.80B | 1.18B | 11.00B | 14.58B |
| 2025 FY | 31.00B | 16.72B | 1.60B | 10.80B | 14.28B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 2.17B | -723.99M | 1.44B | -395.56M | -207.87M |
| 2023 FY | 2.63B | -684.60M | 1.94B | -328.62M | 153.44M |
| 2024 FY | 2.39B | -699.36M | 1.69B | -349.16M | -241.90M |
| 2025 FY | 2.58B | -879.24M | 1.70B | -405.84M | 558.32M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 17.90B | 29.84B | — | — | — |
| 2023 FY | 11.29B | 21.96B | — | — | — |
| 2024 FY | 12.85B | 22.68B | — | — | — |
| 2025 FY | 11.81B | 21.00B | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 4.79B | 1.21B | 394.40M | 225.27M | 0.39 |
| 2025 Q3 | 4.88B | 1.24B | 501.72M | 274.80M | 0.47 |
| 2025 Q4 | 5.07B | 1.39B | 548.98M | 327.08M | 0.57 |
| 2026 Q1 | 4.61B | 1.18B | 375.56M | 117.53M | 0.22 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 31.29B | 16.96B | 1.72B | 11.02B | 13.27B |
| 2025 Q3 | 30.89B | 16.98B | 1.26B | 10.47B | 12.95B |
| 2025 Q4 | 31.00B | 16.72B | 1.60B | 10.80B | 14.28B |
| 2026 Q1 | 31.47B | 17.26B | 1.24B | 11.03B | 13.24B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | 774.93M | -154.38M | 620.55M | -422.52M | 641.45M |
| 2025 Q3 | 741.56M | -192.21M | 549.35M | — | -463.92M |
| 2025 Q4 | 974.54M | -410.42M | 564.11M | -2.19M | 342.43M |
| 2026 Q1 | 226.89M | -190.07M | 36.82M | — | -359.97M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 14.23B | 23.54B | — | — | — |
| 2025 Q3 | 13.12B | 22.33B | — | — | — |
| 2025 Q4 | 11.59B | 20.79B | — | — | — |
| 2026 Q1 | 10.74B | 20.53B | — | — | — |